NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Technology News / Russia's Sputnik V at least 91% effective, early data suggests
    Next Article
    Russia's Sputnik V at least 91% effective, early data suggests

    Russia's Sputnik V at least 91% effective, early data suggests

    By Siddhant Pandey
    Nov 24, 2020
    07:51 pm

    What's the story

    The Russian vaccine for COVID-19, called Sputnik V, has been found at least 91% effective in the second interim analysis.

    According to a press release, the vaccine was found to be 91.4% effective seven days after the second dose was administered, and 95% effective two weeks later.

    Notably, human trials for the vaccine are set to begin in India this week.

    Data

    8 out of 39 participants who contracted COVID-19 received vaccine

    An analysis conducted seven days after the second dose (28 days after the first dose) found the vaccine to be 91.4% effective.

    Out of the 18,794 trial participants, 14,095 had received the vaccine dose while 4,699 were in the placebo group (in a 3:1 ratio).

    Of the 39 confirmed COVID-19 infections among participants, only eight were those who had received the vaccine.

    Information

    21 days after second dose, over 95% efficacy observed

    Preliminary data from volunteers obtained 21 days after the second dose—42 days after the first dose—indicated efficacy of above 95%, the press release stated. Notably, as of Tuesday, over 22,000 participants had received the first dose, while over 19,000 had received first and second doses.

    Analysis

    Final data will be available after Phase III trials

    As per protocol, Sputnik V's interim efficiency is to be calculated when COVID-19 infections among trial participants reach 20, 39, and 78.

    The latest data is from the second interim analysis when 39 cases have been confirmed.

    The next interim data will be conducted when there are 78 COVID-19 cases among participants.

    Final data will be available after Phase III trials conclude.

    Trials

    No unexpected adverse events observed during trials

    Currently, there are 40,000 participants in Phase III double-blind, randomized, placebo-controlled clinical post-registration study of the Sputnik V vaccine in Russia.

    There were no unexpected adverse events during the trials, the release said. However, participants continue to be monitored currently.

    Gamaleya Center will provide access to the full clinical trial report after the Phase III trials are complete.

    Quote

    'We believe final results will exceed expectations'

    Mikhail Murashko, Minister of Health of the Russian Federation, said, "The data demonstrating high efficacy of the Sputnik V vaccine gives us hope that we will soon obtain the most important tool in the fight against the pandemic of the novel coronavirus infection."

    Meanwhile, Alexander Gintsburg, Gamaleya Center Director, said they had "every reason to believe that the (final) results will exceed our expectations."

    Quote

    'Our vaccine's price two times lower than competitors'

    RDIF CEO Kirill Dmitriev said, "Gamaleya Center has developed one of the most efficient vaccines against coronavirus in the world with an efficacy rate of more than 90% and a price that is two times lower than that of other vaccines with similar efficacy rate."

    Dmitriev said the "use of two different human adenoviral vectors...allows for a stronger and longer-term immune response."

    Information

    How have the other vaccine candidates fared?

    Among other leading vaccine candidates, Moderna has said that its product has 94.5% efficacy. Pfizer and BioNTech's vaccine candidate has been found 95% effective, while Oxford University and AstraZeneca's candidate—dubbed 'Covishield' in India—has an average efficacy of 70%, which can be increased to 90% through dosing.

    India

    India to receive 100 million doses of Sputnik V

    Earlier it had been reported that Phase II-III combined trials for Sputnik V will start in India this week.

    The Hyderabad-based Dr. Reddy's Laboratories has struck a deal to conduct vaccine trials and distribution of the vaccine in India.

    India is expected to receive 100 million doses of the potential vaccine, developed jointly by the Russian Direct Investment Fund (RDIF) and the Gamaleya Institute.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Oxford University
    Moderna Inc
    Sputnik V

    Latest

    'Good Sex': All about Netflix romcom featuring Natalie Portman-Mark Ruffalo  Mark Ruffalo
    Mitchell Santner floors Delhi Capitals with 3/11: Key stats Mitchell Santner
    IPL 2025, MI beat DC: How the Impact Players fared Indian Premier League (IPL)
    Mumbai Indians reach IPL 2025 playoffs; DC get eliminated: Stats Mumbai Indians (MI)

    Oxford University

    After US, Russia targeting Indian elections: Oxford University expert Russia News
    Pakistan poses greater threat to humanity than Syria, report finds Pakistan News
    Study: Seven moral rules exist across societies around the world Research
    By 2070, Facebook could have more dead than living users Facebook

    Moderna Inc

    Moderna's COVID-19 vaccine gets FDA nod for phase 2 trial Oxford University
    Moderna's COVID-19 vaccine shows 'positive' results in human trials United States of America
    Why the vaccine for COVID-19 is still several months away Moderna Therapeutics
    Moderna's COVID-19 vaccine: When will it be available? COVID-19

    Sputnik V

    Sputnik V: Russia's COVID-19 vaccine goes into production Russia News
    Russia looking to partner with India for COVID-19 vaccine production Russia News
    Sputnik V phase 3 trials could be conducted in India Russia News
    Sputnik V: Russia starts public distribution of COVID-19 vaccine Russia News
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025